1st Edition

Bioprocessing of Viral Vaccines

Edited By Amine Kamen, Laura Cervera Copyright 2023
328 Pages 74 B/W Illustrations
by CRC Press

328 Pages 74 B/W Illustrations
by CRC Press

328 Pages 74 B/W Illustrations
by CRC Press

This book focuses on cell culture-produced viral vaccines to meet the needs of the rapidly expanding research and development in academia and industry in the field. This book introduces the basic principles of vaccination and the manufacturing of viral vaccines. Bioprocessing of Viral Vaccines, will provide an overview of the advanced strategies needed to respond to the challenges of new and... Read more

Contents

Editors ......................................................................................................................vii

List of abbreviations.................................................................................................ix

Chapter 1 Bioprocessing of viral vaccines–Introduction ................................1

Amine Kamen and Laura Cervera

Chapter 2 Introduction to virology..................................................................17

Shantoshini Dash

Chapter 3 Introduction to basic immunology and vaccine design ..............35

Alaka Mullick and Shantoshini Dash

Chapter 4 Cell lines for vaccine production...................................................57

Isabelle Knott, Jean-Philippe Matheise, Isabelle Ernest, and Jean-Pol Cassart

Chapter 5 Upstream processing for viral vaccines–General aspects...........79

Lars Pelz, Sven Göbel, Karim Jaen, Udo Reichl, and Yvonne Genzel

Chapter 6 Upstream processing for viral vaccines-Process

intensification .................................................................................137

Sven Göbel, Lars Pelz, Udo Reichl, and Yvonne Genzel

Chapter 7 Downstream processing of viral-based vaccines........................175

Rita P. Fernandes, Cristina Peixoto, and Piergiuseppe Nestola

Chapter 8 Analytics and virus production processes ..................................201

Emma Petiot

Chapter 9 Manufacturing of seasonal and pandemic influenza

vaccines–A case study ...................................................................225

Cristina A. T. Silva, Shantoshini Dash, and Amine Kamen

Chapter 10 Recombinant vaccines: Gag-based VLPs ...................................239

Laura Cervera, Irene González-Domínguez, Jesús Lavado-García, and Francesc Gòdia

Chapter 11 Vectored vaccines ..........................................................................269

Zeyu Yang, Kumar Subramaniam, and Amine Kamen

Chapter 12 Design and production of vaccines against COVID-19

using established vaccine platforms ............................................293

Ryan Kligman, Jesús Lavado-García, and Amine Kamen

Index......................................................................................................................315

Biography

Amine Kamen is a professor of bioengineering at McGill University, and Canada

Research Chair in bioprocessing of viral vaccines. He is a researcher emeritus of the

National Research Council of Canada (NRC) where he was employed until early

2014, as head of the Process Development section of the Human Health Therapeutics

Portfolio. At NRC, he established one of North America’s largest and most advanced

governmental centers for animal cell culture addressing process development and

scale-up of biologics. Also, he developed with his team and licensed to industry

multiple technology platforms for efficient manufacturing of recombinant proteins

and viral vectors and vaccines and led technology transfer to manufacturing sites for

clinical evaluation and commercialization. His current research activities focus on

uncovering mechanisms associated with cell production of viral vectors and viral

vaccines, cell and metabolic engineering, process control and monitoring, and process

analytical technologies of high-yield productions of viral vectors for gene delivery

and vaccination. He has published over 170 papers in refereed international journals

and acts as a consultant for several national and international private and public

organizations.

Laura Cervera is a Chemical Engineer from Universitat Autònoma de Barcelona

(Barcelona, Spain). After graduating she did her PhD in Biotechnology on the topic

“Strategies for improving production levels of HIV-1 VLPs by transient transfection

of HEK 293 suspension cultures”. Then she moved to McGillUniversity (Montreal,

Canada) to pursue her research on VLP production, this time using Insect cells as a

platform. She came back to Barcelona to join a project on AAV production for gene

therapy applications using HEK 293 cells.